RxDoctor Payments Data

Naghma Mustafa

Family · Williamsville, NYNPI 1548748411

Payments from drug & device makers

$1,640in general payments, 2019–2025

Across 41 payments — averaging $40.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tandem Diabetes Care, Inc.$253
  • Novo Nordisk$213
  • Lilly USA, LLC$190
  • Sanofi-aventis U.S. LLC$160
  • Amgen$159
  • Sequel Med Tech, LLC$154
  • plus $511 from 8 others

What the payments were for

  • Food & beverage$1,54394%
  • Education$976%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,640 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$37,489
Medicare patients
132
Services billed
744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide610$1,011,314
JardianceEmpagliflozin356$475,320
MounjaroTirzepatide331$398,284
TrulicityDulaglutide253$363,596
RybelsusSemaglutide51$92,921
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog116$55,766
Tresiba Flextouch U-200Insulin Degludec27$53,761
FarxigaDapagliflozin Propanediol43$44,307
Tresiba Flextouch U-100Insulin Degludec39$39,556
Lantus SolostarInsulin Glargine,hum.Rec.Anlog210$38,847
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$30,130
InvokanaCanagliflozin16$26,483
VascepaIcosapent Ethyl30$21,062
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$16,450
Humalog Kwikpen U-100Insulin Lispro75$15,629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$213$1,104,235661 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$190$764,857595 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.

Other family in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →